Scandion Oncology has finalized the first 12 patients in the CORIST study

On January 23, 2021 Scandion Oncology A/S ("Scandion" or the "Company") reported it has completed the first 12 patient cohort in the ongoing dose-range finding part of the clinical phase II study with SCO-101 in combination with chemotherapy (FOLFIRI) in patients with drug resistant metastatic colorectal cancer (Press release, Scandion Oncology, JAN 23, 2021, View Source,c3272887 [SID1234574546]). The Company has now received green light from the Data Safety Monitoring Board to move forward with the next treatment cohorts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this first cohort from the CORIST study, all patients received combination treatment with SCO-101 and the chemotherapy regime FOLFIRI. The cohort was utilized to stepwise adjust the dose of chemotherapy when given together with a fixed dose of SCO-101.

First cohort has added significant understanding

CMO Peter Michael Vestlev: "The CORIST study is our first clinical study where SCO-101 is combined with chemotherapy in drug resistant cancer patients who have no further treatment options. The data has added significant understanding of how to proceed with the SCO-101 treatment. I am looking forward to the next cohorts and to perform the second part of this phase II clinical study."

Timeline maintained, readout expected in Q2, 2021

CEO Bo Rode Hansen: "Our clinical team together with the clinical investigators have done a great job in recruiting this many patients within a short time frame despite the COVID-19 situation. We maintain our expectation of a readout in Q2, 2021 from this first part of the CORIST study."

This information is information that Scandion Oncology A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on 23 January 2021.